CD274 and nonpapillary renal cell carcinoma: In addition, and consistent with the literature, blocking the interaction of PD-L1/PD1 with PD-L1 specific monoclonal IgG1 antibodies (avelumab, durvalumab, and atezolizumab) increased the cytotoxic effect of CTLs on ccRCC cells and modulated the cellular metabolism of CTLs (Figure 5).